Novo Nordisk ROA 2010-2024 | NVO

Current and historical return on assets (ROA) values for Novo Nordisk (NVO) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
Novo Nordisk ROA - Return on Assets Historical Data
Date TTM Net Income Total Assets Return on Assets
2024-03-31 $12.99B $43.52B 29.87%
2023-12-31 $12.15B $45.66B 29.18%
2023-09-30 $10.84B $43.82B 27.97%
2023-06-30 $9.51B $41.02B 26.40%
2023-03-31 $8.57B $36.03B 25.53%
2022-12-31 $7.86B $34.16B 24.56%
2022-09-30 $7.66B $32.86B 24.55%
2022-06-30 $7.63B $31.31B 25.53%
2022-03-31 $7.70B $29.73B 27.02%
2021-12-31 $7.60B $30.95B 28.38%
2021-09-30 $7.45B $27.61B 30.28%
2021-06-30 $7.14B $25.63B 30.80%
2021-03-31 $6.74B $22.92B 30.94%
2020-12-31 $6.46B $22.20B 31.14%
2020-09-30 $6.23B $21.97B 31.31%
2020-06-30 $6.13B $20.11B 32.18%
2020-03-31 $6.01B $18.65B 32.53%
2019-12-31 $5.84B $18.83B 32.46%
2019-09-30 $5.62B $18.61B 32.08%
2019-06-30 $5.51B $17.76B 32.73%
2019-03-31 $5.72B $16.76B 34.61%
2018-12-31 $5.91B $16.94B 36.46%
2018-09-30 $6.16B $15.90B 38.86%
2018-06-30 $6.30B $16.53B 39.97%
2018-03-31 $6.11B $15.45B 40.12%
2017-12-31 $5.79B $15.55B 39.27%
2017-09-30 $5.73B $15.47B 39.52%
2017-06-30 $5.65B $14.47B 40.67%
2017-03-31 $5.69B $13.51B 41.77%
2016-12-31 $5.64B $14.49B 42.38%
2016-09-30 $5.59B $13.10B 42.68%
2016-06-30 $5.37B $13.41B 41.31%
2016-03-31 $5.09B $12.18B 40.22%
2015-12-31 $5.19B $13.66B 41.37%
2015-09-30 $5.08B $12.70B 40.42%
2015-06-30 $4.98B $12.05B 39.69%
2015-03-31 $5.03B $11.74B 40.36%
2014-12-31 $4.72B $13.74B 37.96%
2014-09-30 $4.74B $12.69B 39.02%
2014-06-30 $4.72B $11.71B 39.35%
2014-03-31 $4.61B $11.62B 38.83%
2013-12-31 $4.49B $12.53B 38.21%
2013-09-30 $4.38B $12.10B 38.30%
2013-06-30 $4.20B $11.26B 37.42%
2013-03-31 $3.94B $11.06B 35.71%
2012-12-31 $3.70B $11.35B 33.77%
2012-09-30 $3.53B $11.20B 31.65%
2012-06-30 $3.36B $10.54B 29.76%
2012-03-31 $3.24B $10.79B 27.82%
2011-12-31 $3.16B $12.09B 27.16%
2011-09-30 $3.06B $11.78B 26.94%
2011-06-30 $2.94B $11.88B 27.03%
2011-03-31 $2.77B $10.82B 26.76%
2010-12-31 $2.62B $10.95B 25.77%
2010-09-30 $2.35B $9.89B 23.53%
2010-06-30 $2.23B $9.76B 22.20%
2010-03-31 $2.15B $10.07B 21.61%
2009-12-31 $2.03B $10.25B 21.13%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $598.098B $33.708B
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $834.732B 120.64
Johnson & Johnson (JNJ) United States $366.658B 14.54
Merck (MRK) United States $315.030B 57.32
AbbVie (ABBV) United States $305.760B 15.80
AstraZeneca (AZN) United Kingdom $245.469B 21.34
Novartis AG (NVS) Switzerland $220.139B 15.30
Pfizer (PFE) United States $167.164B 20.77
Sanofi (SNY) $127.725B 12.04
Innoviva (INVA) United States $1.113B 7.82